|
Vaccine Detail
Lymphoma DNA vaccine VαVβVβ-FrC |
Vaccine Information |
- Vaccine Name: Lymphoma DNA vaccine VαVβVβ-FrC
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0004398
- Type: DNA vaccine
- Status: Research
- Host Species as Laboratory Animal Model: Mouse
- Fragment C from tetanus toxin
gene engineering:
- Type: DNA vaccine construction
- Description: This vaccine encoded T-cell antigen receptor Valpha, Vbeta, and Fragment C (Thirdborough et al., 2002).
- Detailed Gene Information: Click Here.
- DNA vaccine plasmid:
- DNA vaccine plasmid name:
- DNA vaccine plasmid VO ID: VO_0000132
- Immunization Route: Intramuscular injection (i.m.)
|
Host Response |
Mouse Response
- Vaccine Immune Response Type: VO_0000286
- Efficacy: Vaccination with the DNA construct VαVβCβ-FrC induced strong protection against challenge with C6VL, compared with nonvaccinated control mice and mice vaccinated with FrC alone (P < 0.001). Vaccinations with VαVβ-FrC, VβCβ-FrC, or VαVβCβ alone were also completely ineffective. The protective response generated was specific for C6VL, with no protection induced against TCL-1, an unrelated T-cell tumor. The pattern of protection has been confirmed in two subsequent experiments, with survival rates of mice vaccinated with VαVβCβ-FrC ranging from 50 to 80%, whereas the other constructs were ineffective at prolonging survival (Thirdborough et al., 2002).
|
References |
Thirdborough et al., 2002: Thirdborough SM, Radcliffe JN, Friedmann PS, Stevenson FK. Vaccination with DNA encoding a single-chain TCR fusion protein induces anticlonotypic immunity and protects against T-cell lymphoma. Cancer research. 2002; 62(6); 1757-1760. [PubMed: 11912151].
|
|